CN102133253B - Application of affine cudweed extractive in preparing medicaments for preventing and curing chronic infectious arthritis - Google Patents
Application of affine cudweed extractive in preparing medicaments for preventing and curing chronic infectious arthritis Download PDFInfo
- Publication number
- CN102133253B CN102133253B CN201110059384A CN201110059384A CN102133253B CN 102133253 B CN102133253 B CN 102133253B CN 201110059384 A CN201110059384 A CN 201110059384A CN 201110059384 A CN201110059384 A CN 201110059384A CN 102133253 B CN102133253 B CN 102133253B
- Authority
- CN
- China
- Prior art keywords
- herba gnaphalii
- gnaphalii affinis
- extractive
- affine cudweed
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The invention discloses application of an affine cudweed extractive in preparing medicaments for preventing and curing chronic infectious arthritis. By experiments, the affine cudweed extractive has the applications that (1) an in-vitro anticomplement activation classic approach cell hemolysis test confirms that the affine cudweed extractive has a stronger anticomplement activity and can be used for autoimmunity inflammation diseases caused by abnormal anticomplement activation; (2) in a model experiment that foot sole acute inflammation of a mouse is caused by carrageenin, a result shows that the affine cudweed extractive has an obvious action on inhibiting the foot tumescence of the mouse; and (3) in an experiment that the affine cudweed extractive has the action on preventing and curing II type collagen chronic infectious arthritis of a rat, a result indicates that the affine cudweed extractive has an extremely obvious action on inhibiting the foot sole tumescence of a rat model with chronic infectious arthritis induced by II type collagen. Therefore, the invention provides a new approach for clinically curing the chronic infectious arthritis, and the preparation method of the affine cudweed extractive is simple and convenient and has a larger actual application value.
Description
Technical field
The present invention relates to plant extract, be specifically related to the application of plant extract, relate in particular to the application of Herba Gnaphalii Affinis extract in preparation control medicine for treating rheumatoid arthritis.
Background technology
Rheumatoid arthritis is to be master's autoimmune disease with the synovium of joint chronic inflammatory disease, can cause arthralgia, causes cartilage destruction then, and the joint space narrows down, and late period, deformity in various degree finally appearred in joint deformity.China prevalence be that 0.3%～0.4%, 70% patient can be disabled after 3 years, average life shortens 10～15 years, has influenced people's quality of life greatly.The medicine of for this reason, researching and developing out effective resisting rheumatoid arthritis has extremely important meaning.
In addition; Complement system is one of immune defense system of wanting of body weight for humans; The improper activation of complement system can cause human immune system's overreaction, causes the damage and the inflammatory reaction of human body self normal structure, is the important medium of autoimmune inflammation reaction.Research shows, the improper activation of complement can cause rheumatoid arthritis, systemic lupus erythematosus (sle) (SLE) etc. various with autoimmune relevant disease out of control.
Herba Gnaphalii Affinis is the dry herb of Compositae cottonweed Herba Gnaphalii Affinis (Gnaphalium affine D.Don).Herba Gnaphalii Affinis has another name called common mouse ear, affine cudweed, and property is sweet, little acid, and flavor is flat, returns lung meridian; Has preventing phlegm from forming and stopping coughing, expelling wind and removing dampness, the effect of detoxifcation; Cure mainly cough with copious phlegm, rheumatic arthralgia is had loose bowels, edema, leucorrhea with red and white discharge, diseases such as carbuncle furuncle.Herba Gnaphalii Affinis main product Jiangsu, zhejiang and other places, aboundresources; Mainly contain compositions such as flavone, organic acid, triterpene, polysaccharide (1, Chem Pharm Bull, 1974,22 (8): 1800; 2, Journal of Agricultural and Food Chemistry, 2000,48 (5): 1888; 3, Biosci Biotechnol Biochem, 2003,67 (10): 2068).
It is reported that the Herba Gnaphalii Affinis water extract has stronger inhibitory action (Sichuan food and fermentation, 2006,42 (6): 53-56) to common pathogens such as staphylococcus aureus, Salmonella, bacillus subtilis, escherichia coli; The water extract can prolong the cough latent period of mice, Cavia porcellus, reduces the cough number of times, can obviously promote the mice tracheal cilia that phenol red secretion is discharged, and shows expectoration effect preferably (Zhejiang University of Traditional Chinese Medicine's journal, 2006,30 (4): 352-353); The Radix Tripterygii Wilfordii wine that medicine compatibilities such as Herba Gnaphalii Affinis and Radix Tripterygii Wilfordii, Radix Aconiti head, Radix Angelicae Sinensis, Rhizoma Homalomenae are processed has successfully been cured wind plug resistance network type rheumatoid arthritis 55 examples (Chinese practical Chinese and western medicine magazine, 2006,19 (18): 2169-2171).But do not see that so far relevant Herba Gnaphalii Affinis extract is used to treat the report of rheumatoid arthritis aspect.
Summary of the invention
Technical problem to be solved by this invention is to study the Herba Gnaphalii Affinis extract, the application of design Herba Gnaphalii Affinis extract in pharmacy.
The present invention provides the application of a kind of Herba Gnaphalii Affinis extract in preparation control medicine for treating rheumatoid arthritis.
Herba Gnaphalii Affinis extract according to the invention obtains through following method:
After the Herba Gnaphalii Affinis pulverizing; Ethanol heat with 20%～80% is carried (70～90 ℃) 3 times; Each consumption is 6～10 times of volumes (6～10L ethanol/kg Herba Gnaphalii Affinis weight) of Herba Gnaphalii Affinis weight, and each extraction time is 2 hours, merges behind 3 extracting solution 50～60 ℃ and is evaporated to dried; Put into 50～60 ℃ of baking ovens then and further be dried to constant weight, get the Herba Gnaphalii Affinis extract.
The Herba Gnaphalii Affinis raw material can obtain through commercially available.
Herba Gnaphalii Affinis extract according to the invention proves that through following effect experiment it has the effect of the rheumatoid arthritis of preventing and treating.
(1) external anticomplementary activates classical pathway cell hemolytic test
1: 10 diluent of human serum is as complement, with the antibody of anti-sheep red blood cell with VBS
2+Buffer dilution be 1: 1000 as hemolysin, add then 2% sheep red blood cell ((SRBC), the activating complement classical pathway causes sheep red blood cell haemolysis (Carbohydrae Research; 2009; 344 (11): 1319-1324), record Herba Gnaphalii Affinis extract of the present invention and can suppress cell haemolysis, CP
50=20 μ g/mL.Experiment confirm Herba Gnaphalii Affinis extract of the present invention has strong ACA, can be used for the autoimmune inflammation disease that the improper activation of complement causes.
(2) cause mice foot sole of the foot acute inflammation model through carrageenin, observe the preventive effect behind the Herba Gnaphalii Affinis extract gastric infusion of the present invention.Experimental result shows; Compare with model group; The high, medium and low dose groups of Herba Gnaphalii Affinis extract has significant inhibitory effect to the mice foot swelling, and its preventive effect is similar basically with positive controls (indomethacin), and high, medium and low three dose groups present certain dose-effect relationship.
(3) the Herba Gnaphalii Affinis extract is to the preventive and therapeutic effect of rat II Collagen Type VI rheumatoid arthritis
Experimental result shows; Herba Gnaphalii Affinis extract of the present invention has utmost point significant inhibitory effect to the inductive rheumatoid arthritis rat model of II Collagen Type VI pedal swelling; The 24th day suppression ratio to the swelling of rat toes reaches the highlyest behind the high, medium and low dose groups gastric infusion, and suppression ratio is respectively 32.98%, 26.80%, 24.29%, and pathological examination shows; The destruction of the fine alleviation articular cartilage of Herba Gnaphalii Affinis extract ability; Prevention synovial cell proliferation degeneration adhesion alleviates joint capsule attachment area congestion of blood vessel edema degree, prevents that inflammatory cell and fibrin from oozing out.It is similar basically that Herba Gnaphalii Affinis extracts object height, its preventive effect of middle dose groups and positive controls (the benefit match is general), and high, medium and low three dose groups present certain dose-effect relationship.
Therefore, Herba Gnaphalii Affinis extract of the present invention can be used for preparing the medicine of preventing and treating rheumatoid arthritis.
Medicine according to the invention is the pharmaceutical composition of being made up of as active component and conventional pharmaceutic adjuvant the Herba Gnaphalii Affinis extract.
Herba Gnaphalii Affinis method for preparing extractive of the present invention is easy, has tangible antiinflammatory, ACA, for the research that prevents and treats rheumatoid arthritis provides the foundation, for the clinical treatment rheumatoid arthritis provides new approach, bigger actual application value is arranged.
Description of drawings
Fig. 1 Herba Gnaphalii Affinis 20%, 50%, 80% ethanol extraction HPLC map
A: Herba Gnaphalii Affinis 20% ethanol extraction; B: Herba Gnaphalii Affinis 50% ethanol extraction; C: Herba Gnaphalii Affinis 80% ethanol extraction.
Fig. 2 Herba Gnaphalii Affinis extract on Carrageenan causes the acutely inflamed preventive effect of the mice foot sole of the foot
A: blank control group; B: model group; C: positive controls; D: high dose group; E: middle dose groups; F: low dose group;
Vertical coordinate is swelling rate (%), and abscissa is for causing scorching back hourage (h).
Fig. 3 Herba Gnaphalii Affinis extract is to the preventive and therapeutic effect of rat II Collagen Type VI rheumatoid arthritis
A: blank control group; B: model group; C: positive controls; D: high dose group; E: middle dose groups; F: low dose group;
Vertical coordinate is swelling rate (%), and abscissa is for causing scorching back natural law (d).
The specific embodiment:
Below in conjunction with embodiment, the present invention is further described
The preparation of embodiment 1 Herba Gnaphalii Affinis extract
The dry herb of Herba Gnaphalii Affinis medical material (purchasing in medical material market, Bozhou, Chinese Anhui) after the pulverizing of 5kg Herba Gnaphalii Affinis herb, is carried (70 ℃) 3 times with 80% ethanol heat; Each 40L, each extraction time is 2 hours, behind the merge extractive liquid; 60 ℃ are evaporated to dried; Putting into 60 ℃ of baking ovens then and further be dried to constant weight, get Herba Gnaphalii Affinis extract 625.0g of the present invention, is 12.5% by crude drug amount yield.
The preparation of embodiment 2 Herba Gnaphalii Affinis extracts
After the pulverizing of 5kg Herba Gnaphalii Affinis herb, carry (80 ℃) 3 times with 50% ethanol heat, each 40L; Each extraction time is 2 hours, and 60 ℃ are evaporated to driedly behind the merge extractive liquid,, put into 60 ℃ of baking ovens then and further are dried to constant weight; Get Herba Gnaphalii Affinis extract 780.3g of the present invention, remember that by the crude drug amount rate is 15.6%.
The preparation of embodiment 3 Herba Gnaphalii Affinis extracts
After the pulverizing of 5kg Herba Gnaphalii Affinis herb, carry (90 ℃) 3 times with 20% ethanol heat, each 40L; Each extraction time is 2 hours, and 60 ℃ are evaporated to driedly behind the merge extractive liquid,, put into 60 ℃ of baking ovens then and further are dried to constant weight; Get Herba Gnaphalii Affinis extract 665.8g of the present invention, remember that by the crude drug amount rate is 13.3%.
The Herba Gnaphalii Affinis extract that embodiment 1,2,3 is obtained advances high performance liquid chromatogram respectively compares, and the result finds that the Herba Gnaphalii Affinis extract component that 3 kinds of method for distilling obtain does not almost have difference, sees Fig. 1
Embodiment 5 Herba Gnaphalii Affinis extract classical pathway complement inhibition tests
Get human serum, with VBS
2+(barbitol buffer solution, pH=7.4 contain 0.5mMMg to buffer
2+With 0.15mM Ca
2+) dilution is 1: 10, as " complement " of classical pathway source.With the antibody of anti-sheep red blood cell with VBS
2+Buffer dilution be 1: 1000 as hemolysin; Sheep red blood cell (SRBC) is used VBS
2+Buffer is configured to 2% sheep red blood cell (SRBC).Precision weighing Herba Gnaphalii Affinis extract (embodiment 1 makes) 2mg adds VBS
2+Buffer 1ml dissolves (the dimethyl sulfoxine hydrotropy of adding 1%), is made into the sample solution of 2mg/ml, uses VBS then
2+Buffer two-fold dilution 1mg/ml, 0.5mg/ml, 0.25mg/ml, 0.125mg/ml, 0.0625mg/ml, 0.03125mg/ml, 0.015625mg/ml, 8 variable concentrations of 0.0078125mg/ml." complement " 0.2ml of the Herba Gnaphalii Affinis extract solution 0.2ml of variable concentrations and 1: 10 is behind 37 ℃ of preincubate 10min; Add anti-sheep red blood cell antibody of 0.1ml (1: 1000) and 0.1ml 2% sheep red blood cell (SRBC) successively;, 37 ℃ of water-baths put into the low-temperature and high-speed centrifuge after hatching 30min; At 5000rpm, centrifugal 10min under 4 ℃ of conditions.Get every pipe supernatant 0.2ml respectively on ELISA Plate, measure absorbance down at ELIASA (Thermo Labsystems, Well scan MK3) 405nm.Experiment is provided with Herba Gnaphalii Affinis extract matched group simultaneously, and (the Herba Gnaphalii Affinis extract solution of 0.2ml respective concentration adds 0.4ml VBS
2+Buffer), the complement control group is (with 0.2ml VBS
2+Buffer replaces the Herba Gnaphalii Affinis extract solution) and full haemolysis group (0.1ml 2% sheep red blood cell (SRBC) is dissolved in three distillatory water of 0.5ml).The Herba Gnaphalii Affinis extract group absorbance of each concentration deducted calculate the haemolysis suppression ratio behind the corresponding Herba Gnaphalii Affinis extract matched group absorbance.As the X axle, the haemolysis suppression ratio is as the mapping of Y axle, the fitting a straight line calculation of half inhibitory concentration CP that obtains with the logarithm of Herba Gnaphalii Affinis extract concentrations
50Value.As positive control drug, the result shows that the Herba Gnaphalii Affinis extract can suppress classical pathway of complement and activate the cell haemolysis that is caused with heparin sodium.The result sees table 1
Table 1 Herba Gnaphalii Affinis extract is to the inhibitory action (
n=3) of complement system classical pathway
1 materials and methods
1.1 laboratory animal
(Chinese Academy of Sciences's Shanghai Experimental Animal Center provides Kunming mouse, the animal quality certification number: SCXK (Shanghai) 2007-0005; Body weight: 18～22g; Sex: male; Every group 10).
1.2 Herba Gnaphalii Affinis extract
The Herba Gnaphalii Affinis extract is by embodiment 1 preparation; Extract is heated to deliquescing for about 60 ℃ in water-bath; Precision takes by weighing Herba Gnaphalii Affinis extract 150mg, 300mg, 600mg respectively then; Add the 10ml0.5% sodium carboxymethyl cellulose, be made into suspension that concentration is respectively 0.12g crude drug/ml, 0.24g crude drug/ml and 0.48g crude drug/ml as the basic, normal, high dose groups of Herba Gnaphalii Affinis extract by yield.
1.3 medication
Administering mode: gastric infusion, once a day.
Dosage: the basic, normal, high dose groups mice of Herba Gnaphalii Affinis extract every day, (dosage was equivalent to 1.2g crude drug/kg, 2.4g crude drug/kg and 4.8g crude drug/kg) by the administration of 0.1ml/10g body weight; Positive control drug indomethacin (Shanghai Xin Pasi pharmaceutical Co. Ltd, specification: 25mg/ sheet, lot number: 070901) be 1mg/kg; Blank control group and model group mice give normal saline by the 0.1ml/10g body weight every day.
1.4 test method
60 kunming mices are divided into 6 groups at random, i.e. blank control group, model group, positive controls (indomethacin), the basic, normal, high dose groups of Herba Gnaphalii Affinis extract.Every mice is pressed the administration of 0.1ml/10g body weight every day, successive administration 3 days, and every mice weighed once every day.After the last administration 1 hour, middle part subcutaneous injection 1% carrageenin 0.1ml causes inflammation in the right back sufficient sole of the foot of mice, with drainage measurements cause scorching before and cause scorching back whenever at a distance from 1 hour pedal swelling value, calculate swelling rate and suppression ratio then.
E
n=cause the swelling value of scorching back different time
E
0=cause the swelling value before scorching
The swelling rate of C=matched group
Experimental data adopts spss13.0 to carry out statistical analysis; Multinomial data relatively adopt one factor analysis of variance between group; Data represent that with
P＜0.05 is as significant difference.
2 experimental results
Mice is respectively organized the body weight change situation before causing inflammation, sees table 2
(data are with mean
expression, g) for the body weight change situation of table 2 mice
Mice cause scorching before and cause scorching back in the time of 1,2,3,4,5,6 hour the pedal swelling value see table 3, figure
Table 3 Ga on Carrageenan causes the acutely inflamed preventive effect of the mice foot sole of the foot (toes volume 0.1ml; N=10,
%)
Annotate: administration group and model group compare, and model group and blank control group be * P＜0.05 relatively, * * P＜0.01; Being swelling rate (%) in (), is suppression ratio (%) in < >
3 conclusions
Before causing inflammation, each experimental mice body weight can both grow steadily, and administration group and blank control group relatively there are not significant difference, explain that the Herba Gnaphalii Affinis extract does not have influence basically to mice normal physiological situation, thereby have guaranteed drug safety.After causing inflammation; Compare with model group; The basic, normal, high dose groups gastric infusion of Herba Gnaphalii Affinis extract has significant inhibitory effect to the mice foot swelling, and its preventive effect is similar basically with positive controls (indomethacin), and high, medium and low three dose groups present certain dose-effect relationship.
Embodiment 7 Herba Gnaphalii Affinis extracts are to the preventive and therapeutic effect of rat II Collagen Type VI rheumatoid arthritis
1 materials and methods
1.1 laboratory animal
(Shanghai west pul-Bi Kai laboratory animal company limited provides the Wistar rat, the animal quality certification number: SCXK2008-0016; Body weight: 120～150g; Sex: male; Every group 10).
1.2 the Herba Gnaphalii Affinis extract is with 1.2 under 5 of the embodiment
1.3 medication and dosage
The basic, normal, high dose groups rat of Herba Gnaphalii Affinis extract every day, (dosage was equivalent to 0.6g crude drug/kg, 1.2g crude drug/kg and 2.4g crude drug/kg) by the administration of 0.1ml/10g body weight; Gastric infusion, once a day.Positive control drug benefit match general (Shanghai CP Guojian Pharmaceutical Co.,Ltd provides, specification: 12.5mg/ props up, lot number: 20100106) be 9mg/kg, the subcutaneous injection administration, per 4 days once; Blank control group and model group rat are pressed the 0.1ml/10g body weight to normal saline, gastric infusion every day.
1.4 experimental technique
The II Collagen Type VI, the pigeon chest cartilage extracts, and (is carried by biology portion of Shanghai Institute of Pharmaceutical Industry collagenase group; Batch number: 080401) be dissolved in the 0.1mol/L acetic acid, making final concentration is 2mg/ml, puts 4 ℃ of refrigerator overnight; Add to cold Fu Shi with II Collagen Type VI drips of solution next day, and (provided by sigma company, lot number is respectively 047K8710,028K8616) fully or in the Freund; Fully emulsified (II Collagen Type VI: Fu Shi fully or Freund=1: 1), making final concentration is 1mg/ml.
Remove blank control group; All the other each groups divide 5 intradermal injection immunities with Freund's complete adjuvant (afterbody and back Intradermal 4 points) at every rat back respectively; Every some 0.1ml is total to 0.5ml, and containing II Collagen Type VI amount is 0.5mg; After 7 days in kind supplementary immunization once (use incomplete Freund), matched group injection 0.1mol/L acetic acid and fully or the incomplete Freund's adjuvant emulsion.Rat random packet behind the 1st injection collagen solution is respectively model group, positive controls, the basic, normal, high dose groups of Herba Gnaphalii Affinis extract, and injecting immune began oral administration, continuous 30 days the same day.Positive controls also began the subcutaneous injection administration the immune same day, and per 4 days once.Different time calculates swelling rate and suppression ratio then with apparatus measures joints of foot swelling value after reaching administration before the administration, and computing formula is following:
E
n=cause the swelling value of scorching back different time
E
0=cause the swelling value before scorching
The swelling rate of C=matched group
The swelling rate of T=administration group
After the anesthesia in the 30th day, animal is put to death in cervical vertebra dislocation, cut open to get ankle joint and be fixed in the formalin, and conventional decalcification, FFPE, section, HE dyeing, microscopically is observed the joint tangent plane, and whether (x40) parenchyma cell or Interstitial cell be intact under every visual field.
Experimental data adopts spss13.0 to carry out statistical analysis; Group difference compares with the t check; Data represent that with
P＜0.05 is as significant difference.
2 experimental results
The Herba Gnaphalii Affinis extract is seen table 4, Fig. 3 to the arthritic preventive and therapeutic effect of rat II Collagen Type VI
Table 4 Herba Gnaphalii Affinis extract is to the arthritic preventive and therapeutic effect of rat II Collagen Type VI (toes volume 0.1ml; N=10,
%)
Annotate: administration group and model group compare, and model group and blank control group be * P＜0.05 relatively, * * P＜0.01; Being swelling rate (%) in (), is suppression ratio (%) in < >
3, pathological examination
Blank control group epiphysis surface compact bone and interior bone spongiosa clear in structure, articular cartilage and synovial cell are complete, do not see cartilage, synovial hyperplasia, degeneration, degradation phenomena, do not see in the articular cavity that inflammatory cell and fibrin ooze out or the collagen fiber deposition; The model group articular surface is coarse, and more serious osteoclasia is arranged, the chondrocyte arrangement disorder; Synovial cell proliferation, synovial membrane degeneration adhesion, synovial layer thickens; Villous shape projection, the articular cavity stenosis is narrow, the synovial cell who has more inflammatory cell and fibrin to ooze out and come off in the articular cavity; The vasodilation of joint capsule attachment area, hyperemia, fibroblast proliferation, collagen fiber deposition.The positive controls articular surface is smooth, the slight hypertrophy of synovial cell, but do not see synovial membrane distortion adhesion and fine hair shape projection; There are a small amount of inflammatory cell and fibrin to ooze out in the articular cavity; Joint capsule attachment area blood vessel mild hyperaemia edema, a small amount of fibroblast proliferation is not seen the collagen fiber deposition.Compare with model group, Herba Gnaphalii Affinis extracts object height, middle dose groups, and articular cartilage is complete basically; More smooth, cell is arranged in order, the slight hypertrophy of synovial cell; Do not see adhesion, have a small amount of inflammatory cell and fibrin to ooze out in the articular cavity, joint capsule attachment area blood vessel mild hyperaemia edema; A small amount of fibroblast proliferation is not seen the collagen fiber deposition.The Herba Gnaphalii Affinis low dose group makes moderate progress than model group; Synovial cell's moderate hypertrophy, even villous shape projection, but do not see synovial membrane distortion adhesion; There are a small amount of inflammatory cell and fibrin to ooze out in the articular cavity; Joint capsule attachment area blood vessel moderate congestion and edema, a small amount of fibroblast proliferation is not seen the collagen fiber deposition.
4 conclusions
Experimental result shows; The Herba Gnaphalii Affinis extract has utmost point significant inhibitory effect to the inductive rheumatoid arthritis rat model of II Collagen Type VI pedal swelling; The 24th day suppression ratio to the swelling of rat toes reaches the highlyest behind the high, medium and low dose groups gastric infusion, and suppression ratio is respectively 32.98,26.80,24.29, and pathological examination shows; The destruction of the fine alleviation articular cartilage of Herba Gnaphalii Affinis extract ability; Prevention synovial cell proliferation degeneration adhesion alleviates joint capsule attachment area congestion of blood vessel edema degree, prevents that inflammatory cell and fibrin from oozing out.It is similar basically that Herba Gnaphalii Affinis extracts object height, its preventive effect of middle dose groups and positive controls (the benefit match is general), and high, medium and low three dose groups present certain dose-effect relationship.
Claims (2)
1. the application of Herba Gnaphalii Affinis extract in preparation control medicine for treating rheumatoid arthritis is characterized in that said Herba Gnaphalii Affinis extract obtains through following method: after Herba Gnaphalii Affinis is pulverized; With 20%～80% ethanol heat carry 70～90 ℃ 3 times; Each consumption is 6～10 times of volume L/kg of Herba Gnaphalii Affinis weight, and each extraction time is 2 hours, merges behind 3 extracting solution 50～60 ℃ and is evaporated to dried; Put into 50～60 ℃ of baking ovens then and further be dried to constant weight, get the Herba Gnaphalii Affinis extract.
2. one kind has the Herba Gnaphalii Affinis preparation method of extract of preventing and treating the rheumatoid arthritis effect, it is characterized in that this method is: after Herba Gnaphalii Affinis is pulverized; With 20%～80% ethanol heat carry 70～90 ℃ 3 times; Each consumption is 6～10 times of volume L/kg of Herba Gnaphalii Affinis weight, and each extraction time is 2 hours, merges behind 3 extracting solution 50～60 ℃ and is evaporated to dried; Put into 50～60 ℃ of baking ovens then and further be dried to constant weight, get the Herba Gnaphalii Affinis extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110059384A CN102133253B (en) | 2011-03-11 | 2011-03-11 | Application of affine cudweed extractive in preparing medicaments for preventing and curing chronic infectious arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110059384A CN102133253B (en) | 2011-03-11 | 2011-03-11 | Application of affine cudweed extractive in preparing medicaments for preventing and curing chronic infectious arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102133253A CN102133253A (en) | 2011-07-27 |
| CN102133253B true CN102133253B (en) | 2012-08-29 |
Family
ID=44293266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110059384A Expired - Fee Related CN102133253B (en) | 2011-03-11 | 2011-03-11 | Application of affine cudweed extractive in preparing medicaments for preventing and curing chronic infectious arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102133253B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101007061A (en) * | 2005-11-28 | 2007-08-01 | 蓝子花 | Dampness-eliminating and pain-relieving medicinal liquor of Ramulus et Folium |
-
2011
- 2011-03-11 CN CN201110059384A patent/CN102133253B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101007061A (en) * | 2005-11-28 | 2007-08-01 | 蓝子花 | Dampness-eliminating and pain-relieving medicinal liquor of Ramulus et Folium |
Non-Patent Citations (4)
| Title |
|---|
| Masakazu Aritomi etc..Dehydro-para-asebotin，a New Chalcone Glucoside in the Flowers of Gnaphalium affine D.Don.《Chem.Pharm.Bull》.1974,第22卷(第8期),1800-1804. * |
| 席忠新等.鼠曲草属植物化学成分与药理作用研究进展.《医药导报》.2010,第29卷(第11期),1462-1466. * |
| 曹晖.中药鼠曲草的本草考证.《江西中医学院学报》.1992,第4卷(第2期),42-43,48. * |
| 钟明等.复方雷公藤酒治疗类风湿关节炎100例远期疗效观察.《中国民间疗法》.2006,第14卷(第9期),62-64. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102133253A (en) | 2011-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102133232B (en) | Cobra venom physical modification method and application in preparation of analgesia or immunosuppressive drugs | |
| WO2021249420A1 (en) | Use of kadsura heteroclita (roxb.) craib agent in preparation of medicament for resisting rheumatoid arthritis | |
| CN105727144A (en) | Traditional Chinese medicine composition for treating bronchitis and preparation method thereof | |
| CN101849999B (en) | Chinese medicinal composition for treating pelvic inflammation and preparation method thereof | |
| WO2014201637A1 (en) | Compound preparation for treating cervical spondylosis with radiculopathy and preparation method therefor | |
| KR20160134925A (en) | Compositions Comprising Extract from Artemisia Princeps Pamp. and Ulmi cortex for Preventing or Treating Osteoarthritis | |
| CN102552825B (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN102579559B (en) | Bauhinia championii ethyl acetate extract, n-butyl alcohol extract, and preparation methods and applications thereof | |
| CN102133253B (en) | Application of affine cudweed extractive in preparing medicaments for preventing and curing chronic infectious arthritis | |
| US8722109B1 (en) | Composition comprising plant extracts and essential oils | |
| CN103877140A (en) | Application of saussurea involucrate culture in preparation of product for promoting bone health | |
| CN110876796B (en) | Traditional Chinese medicine composition for treating acute gout attack and preparation method and application thereof | |
| CN104069183B (en) | There is the Chinese medicine preparation of study of anti-atherogenic effect, preparation method and application | |
| CN102579947B (en) | Chinese medicinal composition and preparation method thereof | |
| CN110123868B (en) | Application of scorpion-containing traditional Chinese medicine composition in preparation of medicine for treating rheumatoid arthritis bone erosion | |
| CN103735851B (en) | A kind of Chinese medicine preparation for the treatment of fracture | |
| CN102846750B (en) | Fengtongning composite preparation and preparation method thereof | |
| CN101711795B (en) | Veterinary antipyretic and antiviral medicine composite | |
| JP6861955B2 (en) | Hyaluronic acid synthesis accelerator | |
| CN108159204B (en) | Tibetan medicine composition with detoxifying and liver protecting effects | |
| CN104189336B (en) | A kind of pharmaceutical composition for the treatment of hyperosteogeny | |
| CN114272343B (en) | Traditional Chinese medicine composition for treating female gouty arthritis and preparation method and application thereof | |
| CA3116793A1 (en) | Medical use of anemoside b4 against acute gouty arthritis | |
| CN109125631A (en) | Chinese medicine composition and preparation method thereof with liver kidney regulatory function | |
| CN104857043A (en) | Radix bupleuri extract and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120829 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |